Currently, there are 443.17M common shares owned by the public and among those 381.07M shares have been available to trade.
The company’s stock has a 5-day price change of 5.26% and 8.01% over the past three months. RPRX shares are trading 7.48% year to date (YTD), with the 12-month market performance down to -22.51% lower. It has a 12-month low price of $25.92 and touched a high of $39.10 over the same period. RPRX has an average intraday trading volume of 2.40 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 5.48%, 7.27%, and 1.45% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Royalty Pharma plc (NASDAQ: RPRX) shares accounts for 65.51% of the company’s 443.17M shares outstanding.
It has a market capitalization of $13.55B and a beta (3y monthly) value of 0.42. The stock’s trailing 12-month PE ratio is 75.44, while the earnings-per-share (ttm) stands at $0.40. The company has a PEG of 23.57 and a Quick Ratio of 13.51 with the debt-to-equity ratio at 1.00. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.38% over the week and 2.33% over the month.
Analysts forecast that Royalty Pharma plc (RPRX) will achieve an EPS of $Catalyst Pharmaceuticals, Inc. for the current quarter, $13.75 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Kiora Pharmaceuticals, Inc. while analysts give the company a high EPS estimate of $Royalty Pharma plc. Comparatively, EPS for the current quarter was $Spear Alpha ETF a year ago. Earnings per share for the fiscal year are expected to increase by 14.52%, and -9.25% over the next financial year. EPS should grow at an annualized rate of 3.20% over the next five years, compared to -45.28% over the past 5-year period.
Looking at the support for the RPRX, a number of firms have released research notes about the stock. UBS stated their Buy rating for the stock in a research note on June 14, 2022, with the firm’s price target at $47.
